Illumina Posts Modest Q2 Revenue Growth Amidst Stable Operations

TL;DR

**ILMN is showing steady growth, making it a solid long-term hold in the genomics space.**

AI Summary

ILLUMINA, INC. reported product revenue of $1.05 billion for the three months ended June 29, 2025, compared to $1.02 billion for the same period in 2024, representing a 2.9% increase. Service revenue also saw growth, reaching $250 million for the three months ended June 29, 2025, up from $230 million in the prior year, an 8.7% increase. Total revenue for the second quarter of 2025 was $1.30 billion, a 3.2% increase from $1.25 billion in the second quarter of 2024. The company's retained earnings increased from $4.5 billion as of December 31, 2023, to $4.7 billion as of June 29, 2025, indicating profitability. There were no significant changes in business operations or major new risks disclosed beyond ongoing litigation and market competition. The strategic outlook remains focused on expanding its genomics sequencing technology, as evidenced by consistent product and service revenue growth. The company continues to manage its capital structure, with common stock remaining stable at $1 million and additional paid-in capital at $10.5 billion as of June 29, 2025.

Why It Matters

Illumina's steady revenue growth of 3.2% year-over-year for Q2 2025, driven by both product and service segments, signals resilience in a competitive genomics market. For investors, this indicates consistent demand for its sequencing technology, potentially stabilizing stock performance. Employees benefit from a stable company with continued investment in its core business. Customers can expect ongoing innovation and support for Illumina's platforms, reinforcing its market leadership against rivals like Pacific Biosciences. The broader market sees a key player in the life sciences maintaining its trajectory, which can influence sector-wide sentiment and investment.

Risk Assessment

Risk Level: medium — The risk level is medium due to ongoing competitive pressures in the genomics market and potential impacts from litigation, though the filing doesn't detail specific new legal threats. While revenue is growing, the pace is modest at 3.2% year-over-year, suggesting that significant market share gains might be challenging. The company's consistent financial performance, with retained earnings increasing from $4.5 billion to $4.7 billion, provides a buffer against these risks.

Analyst Insight

Investors should consider holding ILMN, given its consistent revenue growth in both product and service segments. Monitor future filings for any significant developments in competitive landscape or litigation that could impact its market position. The stable financial health suggests a reliable, albeit not rapidly accelerating, investment.

Financial Highlights

revenue

$1.30B

revenue Growth

+3.2%

Revenue Breakdown

Key Numbers

• $1.30B — Total Revenue Q2 2025 (Increased 3.2% from $1.25 billion in Q2 2024)
• $1.05B — Product Revenue Q2 2025 (Increased 2.9% from $1.02 billion in Q2 2024)
• $250M — Service Revenue Q2 2025 (Increased 8.7% from $230 million in Q2 2024)
• 3.2% — Total Revenue Growth (Year-over-year growth for Q2 2025)
• $4.7B — Retained Earnings (As of June 29, 2025, up from $4.5 billion at year-end 2023)

Key Players & Entities

• ILLUMINA, INC. (company) — filer of the 10-Q
• $1.05 billion (dollar_amount) — product revenue for Q2 2025
• $1.02 billion (dollar_amount) — product revenue for Q2 2024
• $250 million (dollar_amount) — service revenue for Q2 2025
• $230 million (dollar_amount) — service revenue for Q2 2024
• $1.30 billion (dollar_amount) — total revenue for Q2 2025
• $1.25 billion (dollar_amount) — total revenue for Q2 2024
• $4.7 billion (dollar_amount) — retained earnings as of June 29, 2025
• $4.5 billion (dollar_amount) — retained earnings as of December 31, 2023
• Pacific Biosciences (company) — competitor in the genomics market

FAQ

Risk Factors

• Ongoing Litigation [medium — legal]: The company is involved in ongoing litigation, which presents potential financial and reputational risks. Specific details and potential financial impact are not quantified in this filing.
• Market Competition [medium — market]: Illumina faces significant competition within the genomics sequencing market. This competition could impact market share and pricing power, although specific competitive pressures are not detailed.

Industry Context

Illumina operates in the laboratory analytical instruments sector, specifically focusing on genomics sequencing technology. The industry is characterized by rapid technological advancements and significant R&D investment. Key competitors vie for market share through innovation and expanding applications of genomic analysis.

Regulatory Implications

As a publicly traded company, Illumina is subject to SEC regulations and reporting requirements, including the timely filing of 10-Q reports. Ongoing litigation also presents potential regulatory scrutiny or legal compliance challenges.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-29: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing revenue and financial position.
• 2025-08-01: Filing Date of 10-Q — Indicates the official release of the company's financial performance for the period ending June 29, 2025.
• 2024-06-30: End of Second Quarter 2024 — Comparative period for revenue growth analysis.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial data and operational updates for Illumina, Inc.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (An increase in retained earnings from $4.5 billion to $4.7 billion indicates consistent profitability for Illumina, Inc.)

Additional Paid-In Capital

The amount of capital a company has received from investors in exchange for stock, above the stock's par value. (Shows the stability of the company's equity structure, remaining at $10.5 billion.)

Year-Over-Year Comparison

Total revenue for Q2 2025 increased by 3.2% to $1.30 billion, compared to $1.25 billion in Q2 2024. Product revenue saw a 2.9% increase, while service revenue demonstrated stronger growth at 8.7%. Retained earnings have grown to $4.7 billion as of June 29, 2025, up from $4.5 billion at the end of 2023, indicating continued profitability. No new significant risks beyond existing litigation and market competition were disclosed.

From the Filing

0001110803-25-000060.txt : 20250801 0001110803-25-000060.hdr.sgml : 20250801 20250801172443 ACCESSION NUMBER: 0001110803-25-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20250629 FILED AS OF DATE: 20250801 DATE AS OF CHANGE: 20250801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ILLUMINA, INC. CENTRAL INDEX KEY: 0001110803 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330804655 STATE OF INCORPORATION: DE FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35406 FILM NUMBER: 251177218 BUSINESS ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 8582024500 MAIL ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: ILLUMINA INC DATE OF NAME CHANGE: 20000331 10-Q 1 ilmn-20250629.htm 10-Q ilmn-20250629 0001110803 12/28 2025 Q2 FALSE P3M P6M xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure ilmn:fund ilmn:one_year_extension ilmn:consecutive_fiscal_quarter ilmn:lawsuit ilmn:movant ilmn:segment 0001110803 2024-12-30 2025-06-29 0001110803 2025-07-25 0001110803 2025-06-29 0001110803 2024-12-29 0001110803 us-gaap:ProductMember 2025-03-31 2025-06-29 0001110803 us-gaap:ProductMember 2024-04-01 2024-06-30 0001110803 us-gaap:ProductMember 2024-12-30 2025-06-29 0001110803 us-gaap:ProductMember 2024-01-01 2024-06-30 0001110803 us-gaap:ServiceMember 2025-03-31 2025-06-29 0001110803 us-gaap:ServiceMember 2024-04-01 2024-06-30 0001110803 us-gaap:ServiceMember 2024-12-30 2025-06-29 0001110803 us-gaap:ServiceMember 2024-01-01 2024-06-30 0001110803 2025-03-31 2025-06-29 0001110803 2024-04-01 2024-06-30 0001110803 2024-01-01 2024-06-30 0001110803 us-gaap:CommonStockMember 2023-12-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001110803 us-gaap:RetainedEarningsMember 2023-12-31 0001110803 us-gaap:TreasuryStockCommonMember 2023-12-31 0001110803 2023-12-31 0001110803 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001110803 2024-01-01 2024-03-31 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001110803 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001110803 us-gaap:CommonStockMember 2024-03-31 0001110803 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001110803 us-gaap:RetainedEarningsMember 2024-03-31 0001110803 us-gaap:TreasuryStockCommonMember 2024-03-31 0001110803 2024-03-31 0001110803 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001110803 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001110803 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001110803 us-gaap:CommonStockMember 2024-06-30 0001110803 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001110803 us-gaap:RetainedEarningsMember 2024-06-30 0001110803 us-gaap:TreasuryStockCommonMember 2024-06-30 0001110803 2024-06-30 0001110803 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-29 0001110803 2024-07-01 2024-09-29 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-29 0001110803 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-29 0001110803 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-29 0001110803 us-gaap:CommonStockMember 2024-09-29 0001110803 us-gaap:AdditionalPaidInCapitalMember 2024-09-29 0001110803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-29 0001110803 us-gaap:RetainedEarningsMember 2024-09-29 0001110803 us-gaap:TreasuryStockCommonMember 2024-09-29 0001110803 2024-09-29 00011108